Intact Investment Management Inc. trimmed its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 14.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 19,100 shares of the medical instruments supplier's stock after selling 3,250 shares during the period. Intact Investment Management Inc.'s holdings in Becton, Dickinson and Company were worth $4,333,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently bought and sold shares of BDX. Wesbanco Bank Inc. boosted its position in shares of Becton, Dickinson and Company by 1.9% in the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier's stock worth $580,000 after purchasing an additional 48 shares during the last quarter. S.A. Mason LLC boosted its position in shares of Becton, Dickinson and Company by 3.7% in the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier's stock worth $321,000 after purchasing an additional 50 shares during the last quarter. Americana Partners LLC boosted its position in shares of Becton, Dickinson and Company by 3.5% in the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier's stock worth $345,000 after purchasing an additional 52 shares during the last quarter. Novare Capital Management LLC boosted its position in shares of Becton, Dickinson and Company by 5.2% in the 4th quarter. Novare Capital Management LLC now owns 1,110 shares of the medical instruments supplier's stock worth $252,000 after purchasing an additional 55 shares during the last quarter. Finally, Pinnacle West Asset Management Inc. boosted its position in shares of Becton, Dickinson and Company by 2.7% in the 4th quarter. Pinnacle West Asset Management Inc. now owns 2,280 shares of the medical instruments supplier's stock worth $517,000 after purchasing an additional 60 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.
Becton, Dickinson and Company Stock Up 1.9 %
Shares of BDX traded up $4.29 during midday trading on Tuesday, hitting $232.12. The stock had a trading volume of 2,638,307 shares, compared to its average volume of 2,032,361. The company has a 50 day simple moving average of $232.72 and a two-hundred day simple moving average of $232.19. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The firm has a market cap of $66.65 billion, a price-to-earnings ratio of 38.56, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 1.79%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is 69.10%.
Becton, Dickinson and Company announced that its board has initiated a share repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its shares are undervalued.
Analyst Upgrades and Downgrades
BDX has been the topic of several recent research reports. Barclays raised their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. StockNews.com raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, March 5th. Finally, Piper Sandler raised their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 28th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $278.29.
Read Our Latest Research Report on BDX
Insider Buying and Selling at Becton, Dickinson and Company
In related news, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $185,180.00. Following the sale, the executive vice president now owns 16,201 shares of the company's stock, valued at approximately $3,807,235. The trade was a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bertram L. Scott sold 700 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total value of $159,593.00. Following the completion of the sale, the director now directly owns 36,033 shares in the company, valued at approximately $8,215,163.67. This represents a 1.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,363 shares of company stock valued at $1,676,105 in the last 90 days. 0.36% of the stock is currently owned by company insiders.
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Read More
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
